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Abstract
Forced-expression of transcription factors can reprogram somatic cells into induced pluripotent stem cells (iPSC). Recent
studies show that the reprogramming efficiency can be improved by inclusion of small molecules that regulate chromatin
modifying enzymes. We report here that sirtuin 1 (SIRT1), a member of the sirtuin family of NAD+-dependent protein
deacetylases, is involved in iPSC formation. By using an efficient mouse secondary fibroblast reprogramming system with
doxycycline (DOX) inducible Yamanaka’s transcription factors delivered by piggyBac (PB) transposition (2uF/1B MEF), we
show that SIRT1 knockdown decreased while resveratrol (RSV) increased the efficiency of iPSC formation. The treatments
were associated with altered acetylated p53 and its downstream Nanog but not p21 expression. The stimulatory effect was
also confirmed by SIRT1 over-expression, which stimulated the formation of colonies with induced Nanog and reduced p21
expression. Furthermore, the effects of RSV and SIRT1 knockdown on reprogramming were most pronounced during the
initiation phase of reprogramming. MicroRNA-34a is a known regulator of SIRT1. Its inhibitor increased, while its mimics
reduced iPSC formation. The stimulatory effect of SIRT1 during reprogramming was also confirmed in the primary MEF. RSV
increased while tenovin-6, a small molecule that activates p53 through SIRT1 inhibition, suppressed reprogramming. In
conclusion, SIRT1 enhances iPSC generation, in part, through deacetylation of p53, inhibition of p21 and enhancement of
Nanog expression.
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Introduction
Reprogramming of adult somatic cells into induced pluripotent
stem cells (iPSC) is one of the most significant scientific break-
throughs in recent years. iPSCs were first generated from mouse
fibroblasts by the introduction of 4 transcriptional factors
(Yamanaka’s factors), c-Myc, Klf4, Oct4 and Sox2 (MKOS) using
retroviral system [1]. The same four factors were subsequently
reported to reprogram fibroblasts from human [2], monkey [3],
pig [4], rabbit [5] and horse [6], suggesting a conserved
reprogramming mechanism in different species. Functionally,
mouse iPSCs can produce chimeric mice, contribute to germline
transmission, and most importantly generate ‘‘all iPSCs’’ animals
[7–9]. These observations demonstrate that iPSC technology can
potentially be used to generate patient-specific stem cells for
regenerative medicine and to develop a model for studying disease
processes using iPSCs generated from the patient of interest.
Small molecules that remodel chromatin and alter gene
expression increase the reprogramming efficiency in iPSC pro-
duction. For instance, valporic acid (VPA), a class I and II histone
deacetylase (HDAC) inhibitor promotes the generation of mouse
and human iPSCs [10] possibly by enhancing the Oct4 promotor
activity [11]. Another HDAC inhibitor, butyrate also enhances
iPSC generation by increasing acetylation of histone H3 and
demethylation of promoter of pluripotency-related genes [12,13].
Thus, chromatin modification is an important step in reprogram-
ming.
Sirtuin 1 is a member of the sirtuin family of NAD+-dependent
protein deacetylases. It is a class III HDAC and does not respond
to inhibitors of Class I, II, and IV HDACs [14]. It is normally
associated with transcriptional silencing through modulating
chromatin function by direct deacetylation of histones and
promoting alterations in the methylation of histones and DNA.
The latter is accomplished by recruiting histone methylation or
DNA CpG methylation enzymes to chromatin. In addition, the
enzyme can directly interact and deacetylate a number of
transcription factors and coregulators, leading to the positive and
negative regulation of target gene expression (see review in
reference [15]). In mouse ESCs (mESC), SIRT1 blocks nuclear
translocation of p53 and inhibits p53-mediated suppression of
Nanog expression [16]. Differentiation of human ESCs (hESC)
causes down-regulation of SIRT1 and reactivation of key de-
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velopmental genes that are epigenetically repressed by the histone
deacetylase activity of SIRT1 [17]. Whether SIRT1 is involved in
reprogramming by reversion of the above processes is not known.
MicroRNAs (miRNAs) are small non-coding RNAs. ESCs
lacking miRNA biogenesis protein were defective in proliferation
and differentiation [18,19]. The reprogramming efficiency of
mouse iPSCs was enhanced by miRNAs found in ESCs [20,21].
Recently, several miRNAs including miR-181a and b, miR-9,
miR-204, miR-199b, and miR-135a were shown to down-regulate
SIRT1 expression in mESC [22].
We hypothesize that SIRT1 functions as a positive epigenetic
regulator in the maintenance of hESC and the reprogramming of
fibroblasts to iPSCs. In this study, we investigated the roles of
SIRT1 in reprogramming, and found that it stimulated iPSC
formation through the miR-34a-SIRT1-p53 pathway.
Experimental Procedures
Human Embryonic Stem Cell Culture and Differentiation
The hESC line H9 (WiCell Research Institute, Madison, WI)
was maintained in mitomycin C inactivated human foreskin
fibroblast (hFF-1, ATCC, Manassas, VA) using VitroHes (Vitro-
life, Go¨teborg, Sweden) supplemented with 20 ng/ml bFGF
(Invitrogen, Life Technologies, NY, U.S.A) and passaged by
mechanical expansion. For feeder-free experiment, H9 was
enzymatically digested with 1 mg/ml collagenase type IV and
cultured in geltrex matrix coated plates with StemPro (Invitrogen)
medium supplemented with 0.1 mM 2-mercaptoethanol and
10 ng/ml bFGF. To induce differentiation, the medium was
supplemented with retinoic acid (RA) at a concentration of 5 mM
(Sigma, St. Louis, MO) or bone morphogenetic protein 4 (BMP4,
R&D Systems, Minneapolis, MN) at 10 ng/ml in the absence of
bFGF 24 hours after seeding, and cultured for 8 days. H9 cultured
in bFGF supplemented medium for 8 days was used as the control.
H9 was differentiated into embryoid bodies (EB) as described [23]
with some modifications. Briefly, mechanically dissected H9
fragments was centrifuged at 450 g for 5 minutes and allowed to
aggregate in round-bottom low attachment 96-well plate (Nunc,
Kamstrupvej, Roskilde) for 4 days, before transferred to gelatin
coated plate for further attachment growth for 25 days.
Mouse Embryonic Stem Cell Culture and Differentiation
Mouse embryonic stem cells (L4) were obtained from the
Transgenic Core Facility, Department of Biochemistry, The
University of Hong Kong. L4 and miPSC were cultured in
mESC medium [DMEM with high glucose, 100 units/ml
penicillin and 100 mg/ml streptomycin (Gibco, Life Technologies),
0.1 mM MEM non-essential amino-acids (Gibco), sodium pyru-
vate (110 mg/L, Gibco), 50 mM beta-mercaptoethanol, 15% FBS
(Gibco) and 1000 units/ml LIF (Millipore). L4 or miPSC were
differentiated into embryoid bodies using hanging drop method
for the first 2 days followed by 3 days of suspension culture in
ultra-low attachment 96 well plate. The EB was then allowed to
attach to gelatin-coated plate for further culture.
Secondary Mouse Embryonic Fibroblast System, iPSC
Induction and Culture
Secondary PB-iPSC-derived mouse embryonic fibroblasts (2uF/
1B MEF) containing the doxycycline (DOX) inducible MKOS
reprogramming factors and wild type C57BL/6 MEF (wt-MEF)
were isolated as described in [24]. 2uF/1B MEF was seeded at 833
cells/cm2 together with wt-MEF. MKOS was induced with
1.5 mg/ml DOX (Sigma) in mESC medium the following day
after seeding. The iPSC colonies were assessed on day 10, day 15
and day 21 as described in each experiment.
Lentivirus Packaging and Primary Mouse Embryonic
Fibroblast Transduction and Reprogramming
Primary MEF were obtained from ICR mice at 14.5 dpc.
Reprogramming was performed by using lentiviruses produced by
TetO-FUW-mOSKM (Addgene #20321) containing doxycycline
inducible MKOS reprogramming factors cDNAs in a polycistronic
viral vector. 293T cells were transfected with FUW-M2rtTA
(Addgene # 20342) and TetO-FUW-mOSKM (Addgene
#20321) accompanied with pLP1, pLP2, and pLP/VSVG
plasmids (Invitrogen) using lipofectamine 2000 (Invitrogen). Viral
supernatant were harvested at 48 and 72 hours after transfection.
MEFs were infected with the lentiviruses for 24 hours before
exchanged of regular MEF medium. After three days, cells were
split onto gelatin coated plates. Twenty four hours after seeding,
the cells were treated with 1.5 mg/ml DOX in mESC medium for
induction of the Yamanaka’s factors.
Quantitative PCR and Western Blotting
Total RNAs (large and small RNA) were extracted from the
total cells or iPSC colonies by the mirVanaTM miRNA isolation
Kit (Ambion, Life Technologies) following the manufacturer’s
protocol and subjected to reverse transcription using TaqManH
Reverse Transcription Reagents or TaqManH MicroRNA reverse
transcription kit (Applied Biosystems Inc., Life Technologies). Real
time quantitative PCR (qPCR) was performed using the Applied
Biosystems 7500 Real-Time PCR System for the quantification of
mRNA by TaqManH Gene Expression Assays. The detection of
human or mouse Nanog, Sirt1, p21, Snail2 and Cdh1 mRNA was
normalized with the endogenous 18S ribosomal RNA using the
22DDCT method for quantification. The resulting data were
analyzed by the software provided by the manufacturer (Applied
Biosystems Inc.). For immunoblotting, the cells were lysed in cell
lysis buffer (Ambion) containing protease inhibitors (Calbiochem,
Darmstadt, Germany). Equal amount of protein from each sample
was heat inactivated and separated by electrophoresis on 10%
SDS-PAGE and transferred to polyvinylidene fluoride membranes
(PVDF; Immobilon-P, Millipore, Billerica, MA, U.S.A). The
membranes were blotted with antibodies against SIRT1 (Santa
Cruz, CA, U.S.A), OCT4 (Santa Cruz), PCNA (Dako, Denmark),
acetylated p53 (CST, Cell Signaling Technology, Danvers, MA),
p53 (CST) and b-actin (Sigma) followed by appropriate horserad-
ish peroxidase-conjugated secondary antibodies and developed by
enhanced chemiluminescence (Westsave Up, Abfrontier Co. Ltd,
Korea).
Alkaline Phosphatase Activity and Immunocytochemistry
The cells were fixed with 4% paraformaldehyde and washed
with PBST. The alkaline phosphatase activity was determined
by the ES Cell Characterization Kit (Chemicon, Billerica, MA)
following the manufacturer’s protocol. Colonies stained red
indicated positive alkaline phosphatase activity. The expression
of mouse pluripotent markers, SSEA-1 and NANOG was
examined by immunocytochemical staining. The iPSC colonies
15 days post-DOX treatment were fixed with 4% para-
formaldehyde and permeablized with 0.1% Triton before
incubation with antibody against SSEA-1 (Chemicon) and
NANOG (R&D Systems). The fluorescent images were observed
under a confocal microscope (LSM 700, Carl Zeiss AG,
Oberkochen, Germany).
Role of SIRT1 in Reprogramming
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siRNA, SIRT1 Plasmid and miRNA Transfection
2uF/1B MEF were seeded at 1666 cells/cm2 without wt-MEF
and transfected with 100 nM siRNAs (scramble siRNA-A&B and
SIRT1 siRNA, Santa Cruz) with lipofectamine 2000 (Invitrogen)
24 h after seeding. The over-expression of miR-34a was
performed by transfection of 80 nM of Pre-miRTM miRNA
precursor molecule of miR-34a (miR-34a precursor) or control
precursor (Ambion) while knockdown of miRNA was performed
by transfection of 80 nM miRCURY LNATM miRNA knockdown
probe, miR-34a inhibitor or control inhibitor (Exiqon, Vedbaek,
Denmark) according to our established protocol [25]. SIRT1
plasmid pCruzHA SIRT1 (Addgene Plasmid# 10962) were kindly
provided by Dr. Toren Finkel. To over-express SIRT1, pCruzHA
SIRT1 was amplified and 4, 8 or 16 ng/ml of the plasmid was
transfected with lipofectamine 2000. After transfection, the cells
were fed with mESC medium supplemented with DOX thereafter.
RSV and Tenovin-6 Treatments
For RSV treatment, the 2uF/1B MEF was seeded at 833 cells/
cm2 together with wt-MEF and treated with different concentra-
tions of RSV (Sigma) in the presence of DOX. For tenovin-6
(Santa Cruz) treatment, OSKM transduced primary MEF were
seeded at 1666 cells/cm2 and treated with 1 and 5 mM of tenovin-
6 together with DOX. The media were changed every other day.
Proliferation Assay
The proliferation of MEF after transfection of different
concentration of SIRT1 plasmids was performed by The
CyQUANTH NF Cell Proliferation Assay Kit (Invitrogen)
according to the manufacturer instructions. The cells were stained
and the fluorescence was read using excitation at 485 nm and
emission at 530 nm using a plate reader (Tecan Infinite F200, San
Jose, CA).
Statistical Analysis
Data were analyzed and plotted using SigmaPlot software
(Aspire Software International, Leesburg, VA, USA). Statistical
analysis was performed by t-test, Rank Sum test and One Way
ANOVA as appropriate. Significant differences between groups
was considered when p,0.05.
Results
SIRT1 is Down-regulated in Differentiated Human ESCs
Human embryonic stem cell line H9 was either cultured in
bFGF for 6 days or differentiated into EB for 25 days. The
proteins were subjected to Western blot analysis and the relative
SIRT1 expression level was normalized with that of b-actin. The
expression of SIRT1 was high in H9 but was down-regulated to
50% of the undifferentiated level in EBs (Fig. 1A). To confirm if
the down-regulation of SIRT1 during differentiation is lineage
specific, we used RA and BMP4 to induce the differentiation of
epithelial cells [26] and trophoblast cells [27] respectively. Both
RA and BMP4 treatments significantly suppressed OCT4 and
NANOG mRNA expressions (Fig. S1A, B). While RA induced the
expression of epithelial marker, TP63 (Fig. S1A), BMP4 induced
the expression of trophoblast marker, cytokeratin 7 (KRT7, Fig.
S1B). Upon induced differentiation with RA (Fig. 1B) or BMP4
(Fig. 1C) for 8 days, SIRT1 protein levels were significantly
decreased to 20% of the undifferentiated cells. We then set out to
study the temporal expressions of SIRT1 during EB formation and
15 days of RA treatments. It was found that SIRT1 mRNA
dropped drastically in day 8 EB and time-dependently decreased
from day 12 to day 24 (Fig. 1D). RA also suppressed SIRT1
expression time-dependently, which started from day 5 and
progressively thereafter (Fig. 1E). In both differentiation protocols,
the temporal expressions of SIRT1 mRNA were positively
associated with NANOG (Fig. S1F, I) and OCT4 (Fig. S1G, J) but
negatively correlated with the 3 germ layers markers, AMY
(endoderm, Fig. S1C), REN (mesoderm, Fig. S1D) and NEFH
(ectoderm, Fig. S1E) during EB formation and TP63 upon RA
treatment (Fig. S1H). RA treatment induced the expression of the
neuronal marker, b-tubulin III (Fig. 1J). Consistently, nuclear
SIRT1 immunoreactivity, which was strong in the undifferentiated
H9 cells (Fig. 1H), was diminished after 8 days of RA-induced
differentiation (Fig. 1K).
To further determine the relationship between SIRT1 and
expression of pluripotent markers in hESC, we used siRNA to
knockdown SIRT1 expression. As shown by the Western blotting
analysis (Figure 1L), the treatment suppressed the expression of
SIRT1 protein (,30%, Fig. 1L) and decreased the mRNA (50%,
p= 0.031, Fig. S1K) and protein expression of the pluripotent
marker, NANOG (30%, p= 0.01, Fig. 1M), but not that of OCT4
(Fig. S1L and Fig. 1N).
SIRT1 is Up-regulated during Mouse iPSC Formation
To test whether SIRT1 could enhance reprogramming, we used
the secondary mouse fibroblasts reprogramming system efficiently
returning to iPSC state using DOX inducible MKOS transcription
factors delivered by piggyBac (PB) transposons. To generate such
secondary fibroblasts, primary iPSCs were aggregated with
2.5 dpc embryos to produce iPSCs chimaeras, which were then
used to derive ‘‘chimeric’’ secondary mouse embryonic fibroblasts
(2uF/1B MEF) [24]. Upon DOX activation of the MKOS
transgenes, we obtained iPSC like colonies that expressed the
mESC pluripotent cell marker SSEA-1 and NANOG immnor-
eactivities (Fig. S2). These colonies were all GFP positive,
consistent with their generation from iPSCs with constitutive
GFP expression [24].
We set out to study the expression of SIRT1 during
reprogramming of 2uF/1B MEF. We first determined the
temporal change in the expression of Sirt1 during a 20 days’
reprogramming period. Sirt1 mRNA was significantly reduced
upon DOX treatment for the first 6 days, and increased
progressively thereafter. After 20 days’ of reprogramming with
DOX, Sirt1 mRNA was much higher than those cells without
DOX treatment (-DOX). However, the expression level was far
less than in mESC (Fig. 2A). We then collected 2uF/1B MEF
cultured with or without DOX treatment for 15 days and
subjected to Western blotting analysis. Consistent with previous
findings [17], SIRT1 protein was undetectable or barely detected
in MEF. However, a faint band of SIRT1 was detected upon
DOX treatment, and associated with high expressions of OCT4
and proliferating cell nuclear antigen (PCNA) proteins (Fig. 2B,
left). The iPSC like colonies were picked and serially passaged,
SIRT1 signal was enhanced and highly expressed in undifferen-
tiated, but not in differentiated iPSC colonies, indicated that
SIRT1 expression was increased with passages in iPSCs after
reprogramming (Fig. 2B, right). We also compared the protein
levels of SIRT1 in MEF, serially passaged miPSCs and mESCs.
The highest SIRT1 protein level was found in mESCs followed by
miPSCs. The level of SIRT1 in MEF was significantly lower than
mESCs and miPSCs (Fig. 2C). In addition, mESC and serially
passaged iPSC were subjected to EB formation and the samples
were collected on days 2, 5, 8, 11, 14 and 17. Similar to mESCs
(Fig. 2D, left), SIRT1 protein was down-regulated upon differen-
tiation of iPSCs to EBs in a time dependent manner (Fig. 2D,
right).
Role of SIRT1 in Reprogramming
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Figure 1. SIRT1 expression during hESC differentiation. Relative SIRT1 protein levels in undifferentiated H9 cultured in bFGF (ES) for 6 days or
differentiated to EB in differentiating medium for 25 days (A), after RA (B) and BMP4 (C) induced differentiation. Results are shown as the relative
amount of SIRT1 to b-actin levels. (D, E) Time dependent SIRT1 mRNA expressions in EB from Day 4 to Day 24 and after RA treatment for 3 to 15 days.
Role of SIRT1 in Reprogramming
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Knockdown of SIRT1 Suppresses but Resveratrol
Enhances iPSC Formation
The role of SIRT1 during reprogramming was first studied by
transfection of Sirt1 siRNA or control siRNA to 2uF/1B MEF
followed by DOX induction. The iPSC colonies were counted on
day 10 and day 15 after DOX induction. The results showed that
the colony number formed after treatment with Sirt1 siRNA was
three fold lower than that of the control group (p = 0.002 and
p= 0.006 respectively) (Fig. 3A and B). The colonies were collected
on day 15 and subjected to Western Blotting analysis of the
acetylated p53 level. As expected, SIRT1 knockdown increased
the level of acetylated p53 protein by 20% (Fig. 3C).
The expression levels were relative to undifferentiated H9 (D0). *p,0.05 when compared to D0 control. Confocal images showing localization of
SIRT1 (red) and ectoderm marker b-tubulin III (green) in bFGF (F, G, H) or RA treated (I, J, K) H9 cells. Relative NANOG and OCT4 protein expression in
H9 after transfected with control-siRNA or SIRT1-siRNA and normalized with internal control, b-actin. Representative diagram of Western blotting of
SIRT1, NANOG and OCT4 proteins was shown (L, M, N). p-value, Rank Sum Test.
doi:10.1371/journal.pone.0045633.g001
Figure 2. SIRT1 expression during iPSC formation and differentiation of ESCs and iPSCs in mouse model. (A) Temporal expression of
Sirt1 mRNA on day 0 to day 20 after DOX treatment. MEF without DOX on day 20 (20-DOX) and mESC were included. (B) Western blotting analysis of
SIRT1, OCT4 and PCNA in 2uF/1B MEF without (-DOX) and with (+DOX) DOX treatment for 15 days, serially passaged iPSC from passages 4 (P4), 5–7
(P5, P6, P7) and differentiated colonies at passage 4 (Diff-P4). (C) The relative expression levels of SIRT1 protein in MEF, miPSC and mESC. (D) Relative
SIRT1 protein expressions in embryoid bodies collected from mESC and miPSC on days 2, 5, 8, 11, 14 and 17 after differentiation. D0 are the
undifferentiated cell control. *p,0.05 when compared to D0 control. Representative diagrams of Western Blotting of SIRT1 and OCT4 during
embryoid body formation were shown.
doi:10.1371/journal.pone.0045633.g002
Role of SIRT1 in Reprogramming
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We also used a reported SIRT1 activator, resveratrol (RSV)
[28] to treat 2uF/1B MEF during reprogramming. 2uF/1B MEF
was treated with 0.2, 1 or 5 mM of RSV in the presence of DOX.
RSV at concentrations of 0.2 and 1 mM increased the number of
colonies formed from 2uF/1B MEF on both day 10 and day 15
(Fig. 3D and E). The strongest effect was observed with the use of
1 mM of RSV. It resulted in a 6 fold increase in the iPSC colony
formation on day 15, which was significantly (p,0.05) higher than
that of the control (Fig. 3E and F). Higher concentration of RSV
(5 mM) had no effect on the reprogramming efficiency. Western
Blotting analysis also showed that RSV decreased the acetylated
p53 level in the day 15 iPSC colonies (Fig. 3G). The siRNA and
RSV treated colonies were collected and subjected to qPCR
analysis of Nanog and p21 mRNA expression. The results indicated
that Nanog but not p21 mRNA expression was significantly
decreased in iPSC colonies by si-SIRT1 treatment (Fig. 3H and
I) and increased in iPSC colonies by 1 mM RSV treatment (Fig. 3J
and 3K).
Figure 3. Effects of SIRT1-siRNA and RSV on iPSC formation. The relative number of DOX induced iPSC colonies formed on Day 10 (A) and
Day 15 (B) after transfection with control-siRNA or SIRT1-siRNA. The percentage shown was relative to the control groups (n = 6). (C) Western blotting
analysis of acetylated p53 and p53 in Day 15 iPSC colonies was shown. The relative number of iPSC colonies on Day 10 (D) and Day 15 (E) formed
upon treatment with 0.2, 1 and 5 mM RSV (n = 9). Representative alkaline phosphatase staining (F) and Western blotting analysis of acetylated p53
and p53 of Day 15 iPSC colonies was shown (G). *p,0.01 when compared to DOX treatment alone. The relative Nanog and p21 mRNA expressions in
Day 15 iPSC colonies after treatment with siRNA (H, I) or RSV (J, K).
doi:10.1371/journal.pone.0045633.g003
Role of SIRT1 in Reprogramming
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Figure 4. Effects of SIRT1 over-expression on reprogramming. Representative alkaline phosphatase staining of iPSC colonies on Day 15 (A)
and the relative number of iPSC colonies formed upon treatment with 4, 8 and 16 ng/ml Sirt1 plasmid (n = 7) on Day 10 (B) and Day 15 (C). The
relative Nanog (D) and p21 (E), and MET markers, cdh1 (F) and snail2 (G) mRNA expressions in Day 15 iPSC colonies after treatment with 4, 8 and
16 ng/ml of Sirt1 plamids. * p,0.05 when compared to control group.
doi:10.1371/journal.pone.0045633.g004
Role of SIRT1 in Reprogramming
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SIRT1 Over-expression Stimulates iPSC Formation
To further confirm the specificity of SIRT1 effect on
reprogramming, 2uF/1B MEF was transfected with 4, 8 and
16 ng/ml SIRT1 plasmid during reprogramming. SIRT1 over-
expression was confirmed in the cells 3 days post-transfection (Fig.
S3A), and the treatment did not affect cell proliferation (Fig. S3B).
SIRT1 over-expression increased colony formation on both day
10 and day 15 dose-dependently (Fig. 4A–C), in which 8 ng/ml of
plasmid increased 10–15 fold in the number of iPSC colonies
formed on day 15 (Fig. 4C). In addition, the treated colonies
expressed significantly more Nanog (Fig. 4D) but lower p21 (Fig. 4E)
mRNA expressions. SIRT1 over-expression had no effect on
expressions of MET markers, Cdh1 (Fig. 4F) and Snail2 (Fig. 4G).
RSV Acts on the Initiation Phase of Reprogramming
To define the period of action of RSV and si-SIRT1 on
reprogramming of fibroblasts, 2uF/1B MEF was treated with
DOX in the presence of 1 mM RSV at different phases of
reprogramming, namely initiation phase (treatment covered day
1–5), maturation phase (treatment covered day 6–15), stabilization
phase (treatment covered day 16–21) or whole reprogramming
period (treatment covered day 1–21) (Fig. 5A). The colony were
fixed on day 21 and the results showed that the action of RSV in
producing more alkaline phosphatase positive colonies was most
effective in the initiation phase (day 1–5) followed by the
maturation phase (day 6–15). The number of colonies formed
was highest when the treatment covered all the 21 days (Fig. 5B).
To define the action of siRNA, 2uF/1B MEF was transfected with
Sirt1 siRNA or control siRNA on day 1 or day 6 respectively
during the reprogramming process. 2uF/1B MEF transfected with
Sirt1 siRNA on day 1 of DOX induction (D1) formed significantly
fewer iPSC colonies when compared to those transfected on day 6
post-DOX induction (D6) (Fig. 5C–D).
miR-34a is Involved in iPSC Formation
Because SIRT1 has been reported to be a direct downstream
target of miR-34a [29], the effects of miR-34a precursor and
inhibitor on iPSC formation were then followed. 2uF/1B MEF
was transfected with miR-34a precursor or inhibitor. The iPSC
colonies formed were counted on day 10 and day 15, and
compared to their respective controls. The results demonstrated
that while miR-34a precursor inhibited the iPSC formation, miR-
34a inhibitor increased the formation on day 10 (Fig. 6A) and day
15 (Fig. 6B). In addition, SIRT1 protein expression was
significantly up-regulated and down-regulated by miR-34a in-
hibitor and miR-34a precursor (Fig. 6C), respectively, consistent
with a role of miR-34a and SIRT1 in reprogramming.
RSV Promotes and miR-34a Inhibits iPSC Formation in
Primary MEF
Finally, to confirm if the effect of RSV and miR-34a on
reprogramming was not restricted to piggybac transposon and
secondary MEF, we examined primary MEFs transduced with
MKOS-expressing lentivirus. We confirmed that RSV at con-
centrations of 0.1 to 10 mM stimulated a 3-fold increase in iPSC
colony formation (Fig. 7A and B). Consistently, inhibitor of miR-
34a stimulated while its mimics decreased colony formation
(Fig. 7C and D). Besides, we also studied the effect of tenovin-6
that activated p53 through inhibition of the protein-deacetylating
activities of SIRT1 [30] on reprogramming of the primary MEF.
We treated the MEF with 1 and 5 mM tenovin-6 for 24 hours and
found induction of both acetylated and total p53 (Figure S4).
Interestingly, tenovin-6 dose-dependently decreased the colony
formation (Fig. 7E and F), further supported the notion that the
suppressive effect of SIRT1 on p53 is critical for reprogramming.
Figure 5. Temporal effect of SIRT1-siRNA and RSV on iPSC formation. (A) Schematic diagram showing the initiation (D1–5), maturation (D6–
15) and stabilization (D16–21) phase of the reprogramming process. (B) Alkaline phosphatase stainings of iPSCs on day 21 post-DOX induction with
RSV treatments during the reprogramming phases. The relative number of colonies formed on Day 10 (C) and Day 15 (D) after transfection with
control siRNA or Sirt1 siRNA on Day 1 and Day 6 post-DOX treatment. *p,0.05 when compared to control group.
doi:10.1371/journal.pone.0045633.g005
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Discussion
In agreement with the reported finding of SIRT1 down-
regulation in the hESC lines Shef-1 and H-181 during EB
formation [17], we also found that SIRT1 was down-regulated in
the H9 hESC line in a time dependent manner. Furthermore, our
data extended the findings showing that SIRT1 expression was
down-regulated during differentiation of hESC induced by RA
and BMP4. Human ESCs treated with RA produces mainly
ectoderm [26] while BMP4 treatment produces trophoblast
[27,31], primitive endoderm [32,33] and mesoderm [34]. The
correlation of the expression of SIRT1 and NANOG during
differentiation and the SIRT1 knockdown-induced decrease in
NANOG suggest that SIRT1 down-regulation is likely to be an
early event common to differentiation of all cell lineages.
SIRT1 is a protein deacetylase normally associated with
transcriptional silencing through histone deacetylation. It can
modify histone proteins around the genes, thereby modulate gene
expression epigenetically. Apart from acting as histone deacety-
lase, SIRT1 also deacetylates a number of non-histone proteins
including p53 [35]. In tumor cells, SIRT1 deacetylates p53,
leading to change in proliferation/apoptosis via the p53-p21
pathway [36]. In mouse ESCs, SIRT1 regulates apoptosis and
Nanog expressions and protects the cells from oxidative stress via
controlling p53 subcellular localization [16]. Interestingly, we
demonstrated that SIRT1 knockdown led to lower NANOG but
not OCT4 expression in hESCs, suggesting that SIRT1 may
modulate the expression of NANOG through p53 deacetylation.
SIRT1 inhibition increased p53 acetylation [37], leading to the
transactivation of downstream targeting gene of p53, while the
suppression of the p53 pathway has been reported to facilitate
reprogramming [9]. In fact, our previous result also showed that
p53 knockdown in secondary MEF enhanced iPSC formation
[38]. We speculated that SIRT1 might be involved in the
reprogramming process.
Due to the low efficiency in generating primary iPSCs, we
adopted an efficient DOX inducible secondary PB-iPSC-derived
mouse embryonic fibroblasts (2uF/1B MEF) [24] to study the role
of SIRT1 in the entire reprogramming process. In contrast to its
down-regulation during the differentiation of mESC and iPSCs,
SIRT1 expression increased during reprogramming of mouse
fibroblasts, though its level was much lower when compared to
that of mESC. Comparable SIRT1 expression level to that of
mESC was only attained in serially passaged iPSC, which is in line
with the fact that extended passaging of iPSC resulted in enhanced
pluripotency and diminished differential gene expression between
ESCs and iPSCs [39]. The progressive increase of SIRT1 during
passaging suggested that SIRT1 expression may be positively
Figure 6. Effects of miR-34a on reprogramming. Relative number of colonies formed after transfection of miR-34a (34a) precursor and inhibitor
on Day 10 (A) and 15 (B) post-DOX treatment when compared to the corresponding control (Ctl). (C) Relative SIRT1 protein expression upon
transfection with miR-34a precursor and inhibitor after 72 h.
doi:10.1371/journal.pone.0045633.g006
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Figure 7. Effects of RSV, miR-34a and Tenovin-6 on primary MEF reprogramming. The relative number of iPSC colonies formed upon
treatment with 0.1, 0.2, 1, 5 and 10 mM RSV (n = 5) on Day 10 (A) and Day 15 (B). *p,0.05 when compared to DOX treatment alone. Relative number
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correlated with the pluripotency of the reprogrammed iPSCs, in
which the partially reprogrammed iPSCs expressed low levels of
SIRT1. High SIRT1 expression was only attained in fully
reprogrammed cells. SIRT1 is an aging related gene and its
expression decreased with increased population doublings and
serial cell passages [40]. The significant drop of Sirt1 mRNA in the
2uF/1B after 20 days of culture in the absence of DOX could be
due to senescence of the MEFs. However, the increased expression
of SIRT1 during reprogramming suggested that SIRT1 might be
required for the iPSC formation.
Two observations support a role of SIRT1 as an enhancer in
reprogramming. First, knockdown of SIRT1 at the onset of
cellular reprogramming suppressed iPSC production by 3 folds.
The effects of the suppression were more prominent on day 10
after DOX induction when compared to day 15, possibly due to
the dilution effect of SIRT1 siRNA with cell proliferation. Second,
treatment with RSV induced the formation of iPSCs. Recently,
a paper was published concerning the positive effect of RSV on
inducing iPSC formation [41], however the underlying mecha-
nism is not reported. RSV is a plant polyphenol that can increase
the protein expression of SIRT1 [42], and is regarded as a potent
activator of SIRT1 activity [43]. To this end, although we did not
find a significant increase in the Sirt1 expression level after RSV
treatment (data not shown), the stimulatory activity of RSV
through SIRT1 was supported by the reduction of acetylated p53
level, a known substrate of SIRT1. The mechanism is further
supported by analyzing the expression of the SIRT1 downstream
targets in the p53 pathway [16], which showed that Nanog mRNA
expression was significantly increased by RSV but decreased by
SIRT1 siRNA treatments in iPSC colonies. These data are
consistent with the notion that SIRT1 may alleviate the
suppressive role of p53 on Nanog expression during reprogram-
ming.
Apart from SIRT1, RSV has other targets. It reduces the
activation of extracellular signal regulated kinases (ERK) in other
cell types [44,45]. Interestingly, inhibition of ERK promotes the
formation of fully reprogrammed iPSCs [46]. Besides, our data
showed that the iPSCs colony formation efficiency was lower when
the cells were treated with 10 mM RSV than 5 mM RSV on day
15, indicating that higher concentration of RSV may affect other
pathway(s) that inhibit reprogramming. In view of these possibil-
ities, we over-expressed SIRT1 in 2uF/1B MEF to study the
specific action of SIRT1 during reprogramming.
Our result showed for the first time that SIRT1 over-expression
promoted iPSCs formation by 10–15 folds during reprogramming.
The treatment is more potent than RSV (,6 folds) treatment,
mainly due to the fact that SIRT1 over-expression not only
increased the expression of Nanog, but also reduced p21 mRNA
expression dose dependently. The phenomenon was in line with
previous finding that over-expression of SIRT1 strongly attenu-
ated the expression of p53 transcription-dependent apoptosis
targets p21 in cancer cells [47]. On the other hand, we found that
SIRT1 over-expression had no effect on the expression of
mesenchymal-to-epithelial transition (MET) markers, Snail2 (mes-
enchymal) and Cdh1 (epithelial), indicating that SIRT1 may not
contribute to MET in the early phase of reprogramming [38].
Based on gene expression profile analyses of our secondary
fibroblasts, the secondary MEF reprogramming process could be
divided into 3 phases: initiation, maturation and stabilization [38].
In the initiation phase (,Day 1–5 post-DOX treatment), DOX
removal reverts the transcription profile back to the non-DOX
treated basal state. This phase is marked by MET, which is
a critical event during reprogramming. In the maturation phase
(,Day 6-15), the cells become independent of exogenous MKOS
and a subset of pluripotency-associated genes (e.g. Nanog and
Sall4) are induced. In the stabilization phase (.Day 16), re-
finement of the cellular signature and the expressions of other
pluripotent markers occur [38]. The effects of RSV and SIRT1
siRNA were most prominent in the initiation phase of reprogram-
ming. Inhibition of the p53/p21 pathway increases the kinetics of
iPSC formation by enhancing cell division [48] and abrogation of
apoptosis at the onset of iPSC formation [49]. The reduction in
Sirt1 level during the initiation phase (Fig. 2A) may imply less p53
inactivation by SIRT1 deacetylation at this period. So, SIRT1
over-expression or activation at this period could have rescued the
cells undergoing stressful reprogramming.
It has been shown that transcription factors-induced iPSCs
possess an epigenetic memory of their somatic cells origin [50,51],
and treatment of these cells with chromatin-modifying compounds
revert them to fully reprogrammed cells that stably express
pluripotent markers, show an indistinguishable epigenetic pattern
with ESCs and are able to form chimeras. [50]. RSV was most
effective when the treatment covered the whole reprogramming
process. Together with ChIP analysis in other study showing that
SIRT1 preferentially binds to the promoters of genes that are
related to the developmental process in human and mouse ESCs
[17], we postulated that SIRT1 may function as an epigenetic
of colonies formed after transfection of miR-34a (34a) precursor and inhibitor on Day 10 (C) and 15 (D) post-DOX treatment when compared to the
corresponding control (Ctl). The relative number of iPSC colonies formed upon treatment with 1 and 5 mM tenovin-6 (n = 4) on Day 10 (E) and 15 (F).
*p,0.05 when compared to DOX treatment alone.
doi:10.1371/journal.pone.0045633.g007
Figure 8. Schematic diagram showing the pathway of miR-34a-
SIRT1-p53 during reprogramming.
doi:10.1371/journal.pone.0045633.g008
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regulator modulating the gene expression in the early phases to
facilitate reprogramming, possibly through deacetylating lineage-
related factors.
The reprogramming efficiency of miPSCs can be enhanced by
ESC specific miRNAs [20,21]. Several miRNAs down-regulate
SIRT1 expression in mESCs [22]. MiR-34a is a downstream
effector of p53 [52]. In cancer cell lines, miR-34a inhibited Sirt1
expression, leading to an increase in p53 activity and apoptosis
[29]. Our observations that miR-34a precursor down-regulated
while miR-34a inhibitor up-regulated SIRT1 protein expressions
support that Sirt1 is also a direct target of miR-34a in ESCs.
Recently, miR-34a has been shown to be a barrier to reprogram-
ming partly by repression of pluripotency marker genes, including
Nanog. Its expression was significantly up-regulated 3 days after
reprogramming [53]. Interestingly, our data demonstrated a down-
regulation of Sirt1 in the 2uF/1B MEF within the same period of
reprogramming, which might be attributed to the Yamanaka
factors-induced miR-34a up-regulation [53]. These observations
suggest the involvement of a miR-34a-SIRT1-p53 pathway during
reprogramming of MEF. Therefore, we postulate that the induced
miR-34a during the early phase of reprogramming may suppress
SIRT1 expression, leading to its abrogation on p53 inactivation,
and subsequently affecting the reprogramming of mouse fibro-
blasts.
The postulate is supported by two observations. First, miR-34a
precursor inhibited while miR-34a inhibitor and RSV stimulated
iPSC formation in primary and secondary MEFs. A higher
reprogramming efficiency in the secondary MEFs than the
primary MEFs with randomly transfected reprogramming factors
[54] is expected because of lower percentage of cells carrying the
transgenes in the primary system. Second, tenovin-6, a small
molecule that inhibited SIRT1 by suppressing its deacetylation
activity of p53 [55], activated p53 and suppressed iPSC formation
in the primary system.
In conclusion, SIRT1 expression is closely correlated with the
differentiation of ESCs and reprogramming of MEFs. SIRT1
over-expression and SIRT1 activator, RSV promote, while SIRT1
knockdown inhibits iPSCs formation. Such action of SIRT1 is
most potent in the initial phase of reprogramming. SIRT1 acts in
part through deacetylation of p53, inhibition of p21 and
enhancement of Nanog expression. On the other hand, miR-34a
forced expression suppresses reprogramming by suppressing
SIRT1 expression leading to higher p53 activity. These data
together with the stimulatory action of p53 on miR-34a expression
in human ESCs [56] supported the operation of a miR-34a-
SIRT1-p53 loop (Schematic diagram Fig. 8) during early phase of
reprogramming. To our knowledge, this is the first study showing
the role of SIRT1 in the reprogramming process. As prolonged
suppression of p53 may lead to the formation of iPSCs with DNA
lesions and chromosomal aberrations, a transient suppression of
the loop at the initiation phase may be a good compromise in this
respect as the administration of RSV and SIRT1 siRNA in the
initiation phase are most effective in enhancing reprogramming.
Supporting Information
Figure S1 The relative NANOG, OCT4 and TP63 or KRT7
mRNA expression in H9 after induced differentiation with RA (A)
and BMP4 (B); The time dependent mRNA expressions of three
germ layer markers, AMY (C), REN (D) and NEFH (E) and
pluripotent markers, NANOG (F) and OCT4 (G) on Day 4, 8, 12,
16, 20 and 24 during hEB formation; The time dependent mRNA
expressions of TP63 (H), NANOG (I) and OCT4 (J) in H9 after
treatment with RA for 3, 5, 7, 9, 11, 13 and 15 days. D0 is the
undifferentiated control. The relative NANOG (K) and OCT4 (L)
mRNA expressions in H9 after transfected with control-siRNA or
Sirt1-siRNA.
(TIF)
Figure S2 Immunocytochemistry of mESC pluripotent cell
marker SSEA-1(red) and NANOG (red) in the iPSC colonies
formed upon 15 days DOX treatment in 2uF/1B MEF. Green
fluorescent indicated the GFP signal.
(TIF)
Figure S3 (A) Western blotting showing the over-expression of
SIRT1 protein levels after transfection of 8 and 16 ng/ml SIRT1
plasmids. (B) The relative proliferation rate of MEF after
transfection of 4, 8 or 16 ng/ml SIRT1 plasmid.
(TIF)
Figure S4 Western blotting showing acetylated p53, p53 and
PCNA upon treatment with 1 and 5 mM tenovin-6.
(TIF)
Acknowledgments
We thank Kristina Nagy and Peter Tonge for their input on the study. We
also thank the support from the Stem Cell and Regenerative Medicine
Consortium (SCRMC), The University of Hong Kong.
Author Contributions
Conceived and designed the experiments: YLL EHYN AN WSBY.
Performed the experiments: YLL QP SWF ACHC KFL. Analyzed the
data: YLL QP AN WSBY. Wrote the paper: YLL.
References
1. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–
676.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007)
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell 131: 861–872.
3. Liu H, Zhu F, Yong J, Zhang P, Hou P, et al. (2008) Generation of induced
pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 3:
587–590.
4. Esteban MA, Xu J, Yang J, Peng M, Qin D, et al. (2009) Generation of induced
pluripotent stem cell lines from Tibetan miniature pig. J Biol Chem 284: 17634–
17640.
5. Honda A, Hirose M, Hatori M, Matoba S, Miyoshi H, et al. (2010) Generation
of induced pluripotent stem cells in rabbits: potential experimental models for
human regenerative medicine. J Biol Chem.
6. Nagy K, Sung HK, Zhang P, Laflamme S, Vincent P, et al. (2011) Induced
pluripotent stem cell lines derived from equine fibroblasts. Stem Cell Rev 7:
693–702.
7. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, et al. (2009) Adult
mice generated from induced pluripotent stem cells. Nature 461: 91–94.
8. Kang L, Wang J, Zhang Y, Kou Z, Gao S (2009) iPS cells can support full-term
development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 5:
135–138.
9. Zhao Y, Yin X, Qin H, Zhu F, Liu H, et al. (2008) Two supporting factors
greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3: 475–
479.
10. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. (2008)
Induction of pluripotent stem cells from primary human fibroblasts with only
Oct4 and Sox2. Nat Biotechnol 26: 1269–1275.
11. Teng HF, Kuo YL, Loo MR, Li CL, Chu TW, et al. (2010) Valproic acid
enhances Oct4 promoter activity in myogenic cells. J Cell Biochem 110: 995–
1004.
12. Mali P, Chou BK, Yen J, Ye Z, Zou J, et al. (2010) Butyrate greatly enhances
derivation of human induced pluripotent stem cells by promoting epigenetic
remodeling and the expression of pluripotency-associated genes. Stem Cells 28:
713–720.
Role of SIRT1 in Reprogramming
PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e45633
13. Liang G, Taranova O, Xia K, Zhang Y (2010) Butyrate promotes induced
pluripotent stem cell generation. J Biol Chem 285: 25516–25521.
14. Liu T, Liu PY, Marshall GM (2009) The critical role of the class III histone
deacetylase SIRT1 in cancer. Cancer Res 69: 1702–1705.
15. Zhang T, Kraus WL (2010) SIRT1-dependent regulation of chromatin and
transcription: linking NAD(+) metabolism and signaling to the control of cellular
functions. Biochim Biophys Acta 1804: 1666–1675.
16. Han MK, Song EK, Guo Y, Ou X, Mantel C, et al. (2008) SIRT1 regulates
apoptosis and Nanog expression in mouse embryonic stem cells by controlling
p53 subcellular localization. Cell Stem Cell 2: 241–251.
17. Calvanese V, Lara E, Suarez-Alvarez B, Abu DR, Vazquez-Chantada M, et al.
(2010) Sirtuin 1 regulation of developmental genes during differentiation of stem
cells. Proc Natl Acad Sci U S A 107: 13736–13741.
18. Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, et al. (2005)
Dicer-deficient mouse embryonic stem cells are defective in differentiation and
centromeric silencing. Genes Dev 19: 489–501.
19. Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ (2005)
Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl
Acad Sci U S A 102: 12135–12140.
20. Judson RL, Babiarz JE, Venere M, Blelloch R (2009) Embryonic stem cell-
specific microRNAs promote induced pluripotency. Nat Biotechnol 27: 459–
461.
21. Mallanna SK, Rizzino A (2010) Emerging roles of microRNAs in the control of
embryonic stem cells and the generation of induced pluripotent stem cells. Dev
Biol 344: 16–25.
22. Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, et al. (2010)
miRNAs regulate SIRT1 expression during mouse embryonic stem cell
differentiation and in adult mouse tissues. Aging (Albany NY) 2: 415–431.
23. Ng ES, Davis R, Stanley EG, Elefanty AG (2008) A protocol describing the use
of a recombinant protein-based, animal product-free medium (APEL) for human
embryonic stem cell differentiation as spin embryoid bodies. Nat Protoc 3: 768–
776.
24. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, et al. (2009)
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.
Nature 458: 766–770.
25. Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, et al. (2010) MicroRNA-34a
suppresses invasion through downregulation of Notch1 and Jagged1 in cervical
carcinoma and choriocarcinoma cells. Carcinogenesis 31: 1037–1044.
26. Metallo CM, Ji L, de Pablo JJ, Palecek SP (2008) Retinoic acid and bone
morphogenetic protein signaling synergize to efficiently direct epithelial
differentiation of human embryonic stem cells. Stem Cells 26: 372–380.
27. Xu RH, Chen X, Li DS, Li R, Addicks GC, et al. (2002) BMP4 initiates human
embryonic stem cell differentiation to trophoblast. Nat Biotechnol 20: 1261–
1264.
28. Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, et al. (2010) Sirtuin
activators: Designing molecules to extend life span. Biochim Biophys Acta.
29. Yamakuchi M, Ferlito M, Lowenstein CJ (2008) miR-34a repression of SIRT1
regulates apoptosis. Proc Natl Acad Sci U S A 105: 13421–13426.
30. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, et al. (2008) Discovery,
in vivo activity, and mechanism of action of a small-molecule p53 activator.
Cancer Cell 13: 454–463.
31. Golos TG, Pollastrini LM, Gerami-Naini B (2006) Human embryonic stem cells
as a model for trophoblast differentiation. Semin Reprod Med 24: 314–321.
32. Pera MF, Andrade J, Houssami S, Reubinoff B, Trounson A, et al. (2004)
Regulation of human embryonic stem cell differentiation by BMP-2 and its
antagonist noggin. J Cell Sci 117: 1269–1280.
33. Vallier L, Touboul T, Chng Z, Brimpari M, Hannan N, et al. (2009) Early cell
fate decisions of human embryonic stem cells and mouse epiblast stem cells are
controlled by the same signalling pathways. PLoS One 4: e6082.
34. Zhang P, Li J, Tan Z, Wang C, Liu T, et al. (2008) Short-term BMP-4 treatment
initiates mesoderm induction in human embryonic stem cells. Blood 111: 1933–
1941.
35. Guarente L, Picard F (2005) Calorie restriction–the SIR2 connection. Cell 120:
473–482.
36. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159.
37. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. (2006)
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter
cell survival following DNA damage. Mol Cell Biol 26: 28–38.
38. Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, et al. (2010)
Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition
in the initiation of somatic cell reprogramming. Cell Stem Cell 7: 64–77.
39. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, et al. (2009) Induced
pluripotent stem cells and embryonic stem cells are distinguished by gene
expression signatures. Cell Stem Cell 5: 111–123.
40. Sasaki T, Maier B, Bartke A, Scrable H (2006) Progressive loss of SIRT1 with
cell cycle withdrawal. Aging Cell 5: 413–422.
41. Chen T, Shen L, Yu J, Wan H, Guo A, et al. (2011) Rapamycin and other
longevity-promoting compounds enhance the generation of mouse induced
pluripotent stem cells. Aging Cell 10: 908–911.
42. Sun C, Zhang F, Ge X, Yan T, Chen X, et al. (2007) SIRT1 improves insulin
sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 6:
307–319.
43. Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation
by resveratrol. J Biol Chem 280: 17187–17195.
44. Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM (2002)
Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6
kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle
cells. Mol Pharmacol 62: 772–777.
45. Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG (2005) Inhibition of
cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol.
Am J Physiol Heart Circ Physiol 288: H1131–H1138.
46. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, et al. (2008)
Promotion of reprogramming to ground state pluripotency by signal inhibition.
PLoS Biol 6: e253.
47. Yi J, Luo J (2010) SIRT1 and p53, effect on cancer, senescence and beyond.
Biochim Biophys Acta 1804: 1684–1689.
48. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, et al. (2009) Direct cell
reprogramming is a stochastic process amenable to acceleration. Nature 462:
595–601.
49. Marion RM, Strati K, Li H, Murga M, Blanco R, et al. (2009) A p53-mediated
DNA damage response limits reprogramming to ensure iPS cell genomic
integrity. Nature 460: 1149–1153.
50. Kim K, Doi A, Wen B, Ng K, Zhao R, et al. (2010) Epigenetic memory in
induced pluripotent stem cells. Nature 467: 285–290.
51. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, et al. (2010) Cell type of
origin influences the molecular and functional properties of mouse induced
pluripotent stem cells. Nat Biotechnol 28: 848–855.
52. He L, He X, Lim LP, de SE, Xuan Z, et al. (2007) A microRNA component of
the p53 tumour suppressor network. Nature 447: 1130–1134.
53. Choi YJ, Lin CP, Ho JJ, He X, Okada N, et al. (2011) miR-34 miRNAs provide
a barrier for somatic cell reprogramming. Nat Cell Biol 13: 1353–1360.
54. Plath K, Lowry WE (2011) Progress in understanding reprogramming to the
induced pluripotent state. Nat Rev Genet 12 (4): 253–265.
55. Brooks CL, Gu W (2008) p53 Activation: a case against Sir. Cancer Cell 13:
377–378.
56. Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, et al. (2012) p53
regulates cell cycle and microRNAs to promote differentiation of human
embryonic stem cells. PLoS Biol 10: e1001268.
Role of SIRT1 in Reprogramming
PLOS ONE | www.plosone.org 13 September 2012 | Volume 7 | Issue 9 | e45633
